ClinVar Miner

Submissions for variant NM_000546.5(TP53):c.997C>T (p.Arg333Cys) (rs769934890)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000164055 SCV000214662 uncertain significance Hereditary cancer-predisposing syndrome 2017-11-02 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient evidence
Color RCV000164055 SCV000686789 uncertain significance Hereditary cancer-predisposing syndrome 2018-09-05 criteria provided, single submitter clinical testing
GeneDx RCV000485066 SCV000568755 uncertain significance not provided 2017-11-27 criteria provided, single submitter clinical testing This variant is denoted TP53 c.997C>T at the cDNA level, p.Arg333Cys (R333C) at the protein level, and results in the change of an Arginine to a Cysteine (CGT>TGT). This variant was observed in a patient with a history of acute lymphoblastic leukemia (ALL) and Ewing sarcoma (Mitchell 2013). TP53 Arg333Cys is reported as having functional transactivation in the International Agency for Research on Cancer TP53 database based on functional assays by Kato et al. (2003) and was shown to maintain the ability to form the p53 tetramer (Kawaguchi 2005). TP53 Arg333Cys was not observed at a significant allele frequency in large population cohorts (Lek 2016). Since Arginine and Cysteine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. TP53 Arg333Cys is located in the tetramerization domain (Bode 2004). In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. Based on currently available evidence, it is unclear whether TP53 Arg333Cys is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Integrated Genetics/Laboratory Corporation of America RCV000780790 SCV000918344 uncertain significance not specified 2018-07-13 criteria provided, single submitter clinical testing Variant summary: TP53 c.997C>T (p.Arg333Cys) results in a non-conservative amino acid change located in the p53, tetramerisation domain (IPR010991) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 245334 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant, c.997C>T, has been reported in the literature in an individual affected with acute lymphoblastic leukemia (ALL) and Ewing sarcoma, who met the Chompret criteria for Li-Fraumeni Syndrome (Mitchell 2013). This report however does not provide unequivocal conclusions about association of the variant with Li-Fraumeni Syndrome (LFS). In a study evaluating an impact on protein function, the variant protein was found to be able to form tetramers and had a partial transcriptional activity (Kawaguchi 2005), however these data do not allow convincing conclusions about the variant effect. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Invitae RCV000197833 SCV000254647 uncertain significance Li-Fraumeni syndrome 2018-07-19 criteria provided, single submitter clinical testing This sequence change replaces arginine with cysteine at codon 333 of the TP53 protein (p.Arg333Cys). The arginine residue is highly conserved and there is a large physicochemical difference between arginine and cysteine. This variant is present in population databases (rs769934890, ExAC 0.009%). This variant has been reported in an individual affected with acute lymphoblastic leukemia (age 10), and then Ewing sarcoma (age 16) (PMID: 23894400). ClinVar contains an entry for this variant (Variation ID: 184745). Experimental studies have shown that this missense change does not affect the transcriptional transactivation activity of the TP53 protein, or its ability to form tetramers (PMID: 12826609, 16007150). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Mendelics RCV000197833 SCV000839104 uncertain significance Li-Fraumeni syndrome 2018-07-02 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.